Hoge Stephen
President
In the last 12 months, Hoge Stephen filed 69 SEC Form 4 transactions across 1 issuer: $0 in open-market purchases and $28.4M in open-market sales. 30% of these transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $28.4MOpen-market sells (1y)
- 69Transactions filed
- 1Distinct issuers
- 30%Under Rule 10b5-1
- 2026-09-15Latest filing
Issuers Filed For By open-market buy volume
Recent Form 4 Filings Most recent 69 of 69 (1-year window)
| Date | Ticker | Company | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $933.5K | 76,452 | $12.2 |
| 2026-09-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $0 | 76,452 | $0.0 |
| 2026-09-15 | MRNA | Moderna, Inc. | Sell 10b5-1 | S | $5.9M | 40,281 | $146.1 |
| 2026-09-14 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $933.5K | 76,453 | $12.2 |
| 2026-09-14 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $0 | 76,453 | $0.0 |
| 2026-09-14 | MRNA | Moderna, Inc. | Sell 10b5-1 | S | $5.8M | 40,294 | $144.1 |
| 2026-09-01 | MRNA | Moderna, Inc. | Exercise | M | $0 | 9,283 | – |
| 2026-09-01 | MRNA | Moderna, Inc. | Exercise | M | $0 | 9,283 | $0.0 |
| 2026-09-01 | MRNA | Moderna, Inc. | Other | F | $630.0K | 4,489 | $140.3 |
| 2026-08-28 | MRNA | Moderna, Inc. | Exercise | M | $0 | 611 | – |
| 2026-08-28 | MRNA | Moderna, Inc. | Exercise | M | $0 | 611 | $0.0 |
| 2026-08-28 | MRNA | Moderna, Inc. | Other | F | $42.3K | 296 | $142.8 |
| 2026-08-27 | MRNA | Moderna, Inc. | Exercise | M | $0 | 1,437 | – |
| 2026-08-27 | MRNA | Moderna, Inc. | Exercise | M | $0 | 1,437 | $0.0 |
| 2026-08-27 | MRNA | Moderna, Inc. | Other | F | $104.0K | 695 | $149.7 |
| 2026-07-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $712.9K | 37,226 | $19.1 |
| 2026-07-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $308.5K | 16,110 | $19.1 |
| 2026-07-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $0 | 37,226 | $0.0 |
| 2026-07-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $0 | 16,110 | $0.0 |
| 2026-07-15 | MRNA | Moderna, Inc. | Sell 10b5-1 | S | $3.6M | 53,336 | $67.6 |
| 2026-06-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $712.9K | 37,226 | $19.1 |
| 2026-06-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $308.5K | 16,110 | $19.1 |
| 2026-06-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $0 | 37,226 | $0.0 |
| 2026-06-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $0 | 16,110 | $0.0 |
| 2026-06-15 | MRNA | Moderna, Inc. | Sell 10b5-1 | S | $2.7M | 53,336 | $51.4 |
| 2026-06-01 | MRNA | Moderna, Inc. | Exercise | M | $0 | 9,282 | – |
| 2026-06-01 | MRNA | Moderna, Inc. | Exercise | M | $0 | 9,282 | $0.0 |
| 2026-06-01 | MRNA | Moderna, Inc. | Other | F | $211.8K | 4,488 | $47.2 |
| 2026-05-28 | MRNA | Moderna, Inc. | Exercise | M | $0 | 610 | – |
| 2026-05-28 | MRNA | Moderna, Inc. | Exercise | M | $0 | 610 | $0.0 |
| 2026-05-28 | MRNA | Moderna, Inc. | Other | F | $14.0K | 295 | $47.6 |
| 2026-05-27 | MRNA | Moderna, Inc. | Exercise | M | $0 | 1,437 | – |
| 2026-05-27 | MRNA | Moderna, Inc. | Exercise | M | $0 | 1,437 | $0.0 |
| 2026-05-27 | MRNA | Moderna, Inc. | Other | F | $32.7K | 695 | $47.0 |
| 2026-05-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $712.9K | 37,226 | $19.1 |
| 2026-05-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $308.5K | 16,110 | $19.1 |
| 2026-05-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $0 | 37,226 | $0.0 |
| 2026-05-15 | MRNA | Moderna, Inc. | Exercise 10b5-1 | M | $0 | 16,110 | $0.0 |
| 2026-05-15 | MRNA | Moderna, Inc. | Sell 10b5-1 | S | $2.6M | 53,336 | $48.4 |
| 2026-03-01 | MRNA | Moderna, Inc. | Grant | – | $0 | 125,466 | $0.0 |
| 2026-03-01 | MRNA | Moderna, Inc. | Grant | – | $0 | 165,230 | $0.0 |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $0 | 652 | – |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $16.3K | 316 | $51.7 |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $0 | 611 | – |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $15.3K | 296 | $51.7 |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $0 | 1,436 | – |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $35.9K | 695 | $51.7 |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $0 | 37,131 | – |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $928.3K | 17,953 | $51.7 |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $0 | 652 | $0.0 |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $0 | 611 | $0.0 |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $0 | 1,436 | $0.0 |
| 2026-02-27 | MRNA | Moderna, Inc. | Grant | – | $0 | 37,131 | $0.0 |
| 2026-02-23 | MRNA | Moderna, Inc. | Grant | – | $2.1M | 111,679 | $19.1 |
| 2026-02-23 | MRNA | Moderna, Inc. | Grant | – | $925.5K | 48,330 | $19.1 |
| 2026-02-23 | MRNA | Moderna, Inc. | Grant | – | $0 | 111,679 | $0.0 |
| 2026-02-23 | MRNA | Moderna, Inc. | Grant | – | $0 | 48,330 | $0.0 |
| 2026-02-23 | MRNA | Moderna, Inc. | Sell | – | $7.8M | 160,009 | $48.8 |
| 2026-02-11 | MRNA | Moderna, Inc. | Grant | – | $0 | 4,884 | $0.0 |
| 2026-02-11 | MRNA | Moderna, Inc. | Grant | – | $99.2K | 2,362 | $42.0 |
| 2025-12-01 | MRNA | Moderna, Inc. | Grant | – | $0 | 652 | – |
| 2025-12-01 | MRNA | Moderna, Inc. | Grant | – | $8.2K | 316 | $26.0 |
| 2025-12-01 | MRNA | Moderna, Inc. | Grant | – | $0 | 652 | $0.0 |
| 2025-11-28 | MRNA | Moderna, Inc. | Grant | – | $0 | 610 | – |
| 2025-11-28 | MRNA | Moderna, Inc. | Grant | – | $7.4K | 295 | $25.0 |
| 2025-11-28 | MRNA | Moderna, Inc. | Grant | – | $0 | 610 | $0.0 |
| 2025-11-26 | MRNA | Moderna, Inc. | Grant | – | $0 | 1,437 | – |
| 2025-11-26 | MRNA | Moderna, Inc. | Grant | – | $17.2K | 695 | $24.8 |
| 2025-11-26 | MRNA | Moderna, Inc. | Grant | – | $0 | 1,437 | $0.0 |
Methodology & FAQ
How These Filings Are Sourced
All transactions on this page are sourced directly from SEC EDGAR. A complete description of the open-market vs grant distinction, the Rule 10b5-1 plan-reference heuristic, and the per-insider name matching is documented in the Methodology.
What companies does Hoge Stephen file Form 4 disclosures for?
Hoge Stephen has filed SEC Form 4 transactions for 1 issuer in the last 12 months: Moderna, Inc. (MRNA).
What does the 10b5-1 badge mean on these transactions?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Of Hoge Stephen's 69 reported transactions in the last 12 months, 21 (30%) reference a 10b5-1 trading plan in the Form 4 footnotes.
Are these all the transactions Hoge Stephen has executed?
This page shows SEC Form 4 transactions on record in Pactolio's tracked universe for the last 12 months. Form 4 only covers transactions in registered classes of equity at issuers where the person qualifies as an insider (officer, director, or 10% beneficial owner). Trades in funds, foreign issuers, or non-insider positions are not disclosed under Form 4 and are not included here.